Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AM-1638 is a full agonist of GPR40/FFA1 (EC50: 0.16 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 893.00 | |
50 mg | 8-10 weeks | $ 1,160.00 | |
100 mg | 8-10 weeks | $ 1,740.00 |
Description | AM-1638 is a full agonist of GPR40/FFA1 (EC50: 0.16 μM). |
Targets&IC50 | FFA1/GPR40:0.16 μM |
In vivo | AM-1638 demonstrates moderate cross-species plasma clearance and distribution volume, leading to plasma half-lives conducive to the assessment of its antidiabetic effects in mice, rats, and cynomolgus monkeys. It shows antidiabetic activity in BDF/DIO mice[1]. Furthermore, the oral administration of the full agonist AM-1638 reveals superb oral bioavailability, exceeding 100% in mice, and achieving 72% and 71% in rats and cynomolgus monkeys, respectively. |
Molecular Weight | 514.63 |
Formula | C33H35FO4 |
CAS No. | 1142214-62-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (485.79 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AM-1638 1142214-62-7 Endocrinology/Hormones GPCR/G Protein GPR AM1638 AM 1638 inhibitor inhibit